Related Experiment Video
Updated: May 27, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
[First-line bevacizumab in ovarian cancer]
1TAYS:n naistentautien ja synnytysten vastuualue.
Abstract:
Based on encouraging Phase II data, two randomized phase III trials (GOG218 and ICON7) aimed at showing a progression-free survival (PFS) benefit of bevacizumab combined with first-line paclitaxel and carboplatin, followed by maintenance bevacizumab, in ovarian cancer. The median PFS increased to four and two months, respectively, as compared to chemotherapy alone. However, these two trials left important questions like proper patient selection, optimal dose level and length of maintenance phase, unanswered. Neither do we know if the quite modest progression-free survival benefit will translate into an overall survival benefit. Consequently, first-line bevacizumab in ovarian cancer cannot at present be recommended.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

